David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
David Chang is handing over the reins at Allogene; ex-Esperion CEO gets started at Phlow.
Allogene Therapeutics
Allogene Therapeutics (NASDAQ: ALLO) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. Allogene's lead clinical programs include cemacabtagene ansegedleucel (cema-cel, ALLO-501A) for relapsed/refractory large B-cell lymphoma and the ALPHA3 trial of ALLO-329 (a CD19/CD70 dual-allogeneic CAR T) in autoimmune disease. The company was founded in 2017 by acquiring Pfizer's allogeneic CAR-T portfolio and is led by CEO Dr. Zach Roberts as of June 30, 2026.
Company Info
Sector:Allogeneic CAR T Cell Therapy
Headquarters:South San Francisco, California, USA
Founded:2017
Website:allogene.com/
Recent News
Leadership Team
Dr. Zach Roberts
Chief Executive Officer
Careers & Job Openings